FDA Approves Two Gene Therapies for Sickle Cell Disease
Published on
![FDA Approves First CRISPR-Based Therapy for Sickle Cell Disease FDA Approves First CRISPR-Based Therapy for Sickle Cell Disease](https://www.chop.edu/sites/default/files/fda-approves-first-crispr-based-therapy-sickle-cell-disease-16x9.png)
The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).